Skip to main content
. Author manuscript; available in PMC: 2018 Nov 8.
Published in final edited form as: Int Rev Immunol. 2017 Sep 29;36(6):338–351. doi: 10.1080/08830185.2017.1363199

Figure 1.

Figure 1.

Classification systemof immunotherapies for pancreatic ductal adenocarcinoma (PDA). The tumor stroma impedes these therapies withmultiple immunosuppressive mechanisms described in the text. Stromal-directed treatments, such as focused ultrasound, have shown promising results in early clinical trials and may provide substantial clinical benefit as immuno-adjuvant therapy.